posted on 2022-07-20, 08:31authored byJR Attia, E Holliday, N Weaver, R Peel, KC Fleming, A Hure, J Wiggers, Mark McEvoyMark McEvoy, A Searles, P Reeves, P Ranasinghe, R Jayawardena, S Samman, J Luu, C Rissel, S Acharya
Aims: The burden and health costs of Type 2 Diabetes Mellitus continue to increase globally and prevention strategies in at-risk people need to be explored. Previous work, in both animal models and humans, supports the role of zinc in improving glucose homeostasis. We, therefore, aimed to test the effectiveness of zinc supplementation on glycaemic control in pre-diabetic adults. Methods: We conducted a randomized, double-blind, placebo-controlled trial across 10 General Practitioner (GP) practices in NSW, Australia. The trial is known as Zinc in Preventing the Progression of pre-Diabetes (ZIPPeD)Study. Pre-diabetic (haemoglobin A1c [HbA1c] 5.7–6.4%, 39–46 mmol/mol) men and women (N = 98) were all assigned to a free state government telephone health coaching service (New South Wales Get Healthy Information and Coaching Service) and then randomised to either daily 30 mg zinc gluconate or placebo. Blood tests were collected at baseline, 1, 6 and 12 months for the primary outcomes (HbA1c, fasting blood glucose (FBG)); secondary outcomes included Homeostasis Model Assessment 2 (HOMA 2) parameters, lipids, body weight, height, waist circumference, blood pressure and pulse. Results: The baseline-adjusted mean group difference at 6 months, expressed as treatment–placebo, (95% CI) was −0.02 (−0.14, 0.11, p = 0.78) for HbA1c and 0.17 (−0.07, 0.42; p = 0.17) for FBG, neither of which were statistically significant. There were also no significant differences between groups in any of the secondary outcomes. Zinc was well tolerated, and compliance was high (88%). Conclusion: We believe our results are consistent with other Western clinical trial studies and do not support the use of supplemental zinc in populations with a Western diet. There may still be a role for supplemental zinc in the developing world where diets may be zinc deficient. Trial registration: Australian and New Zealand Clinical Trials Registry, ACTRN12618001120268. Registered on 6 July 2018.
Funding
Open Access funding enabled and organized by CAUL and its Member Institutions. This work is jointly supported by the New South Wales (NSW) Ministry of Health Translational Research Grant Scheme (TRGS) for the overall funding of the ZIPPeD study (H18/31636) and Hunter New England Local Health District (HNELHD) integrated care funding allocated by the NSW Ministry Of Health. Blackmores Limited provided the zinc and placebo supplements and funds to support mailing costs. The study funders were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report.
History
Publication Date
2022-07-01
Journal
Acta Diabetologica Latina
Volume
59
Issue
7
Pagination
11p. (p. 965-975)
Publisher
Casa Editrice II Ponte
ISSN
0001-5563
Rights Statement
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.